宫颈阴道微生物群与HPV感染、宫颈上皮内瘤变及宫颈癌的关系:系统评价和网络荟萃分析
Associations of Cervical Vaginal Microflora with HPV Infection, Cervical Intraepithelial Neoplasia and Cancer: A Systematic Review and Network Meta-Analysis
DOI: 10.12677/ACM.2021.112101, PDF,   
作者: 秦 丽, 朱 莉, 王瑞雅, 任志帅, 郭玉琪:郑州大学人民医院(河南省人民医院),河南 郑州
关键词: 阴道微生物人乳头瘤病毒宫颈癌Vaginal Microbiota Human Papillomavirus Cervical Cancer
摘要: 目的:系统评价宫颈阴道微生物群与人乳头瘤病毒(human papillomavirus, HPV)感染、宫颈上皮内瘤变(cervical intraepithelial neoplasias, CIN)和宫颈癌之间的关系。方法:用计算机检索PUBMED、EMBASE、COCHRANE LIBRARY等数据库2010年以来关于宫颈阴道微生物群与HPV感染、宫颈上皮内瘤变和宫颈癌之间的关系的研究,经过筛选后进行系统评价,采用Stata/MP 16.0软件对文献进行网络荟萃分析(network meta-analysis, NMA)。结果:经筛选后共纳入12个研究,共涉及1449例受试者。12项研究中最常见的阴道微生物群落状态类型(community state type, CST)为CST I:卷曲乳杆菌优势的CST、CST III:惰性乳杆菌优势的CST和CST IV:乳酸杆菌缺乏的CST。Meta分析结果证实,阴道菌群以非乳酸杆菌为优势的女性更可能与HPV感染、高危HPV感染、宫颈病变或宫颈癌相关,其中发生HPV感染的合并优势比(odds ratio, OR)为1.78,95%CI (1.29, 2.47),发生高危HPV感染OR = 1.36,95%CI (0.97, 1.88),发生任何宫颈病变或癌症:OR = 2.10,95%CI (1.03, 4.27);对于高危HPV感染的清除或CIN2的消退,非乳酸杆菌优势的CST优势比为0.39,95%CI (0.23, 0.66);而卷曲乳杆菌优势的CST优势比为2.36,95%CI (1.23, 4.52)。任何HPV阳性组、高危HPV阳性组中低乳酸杆菌CST所占加权合并比例均为最高,分别为52%,95%CI (46%, 59%)和49%,95%CI (38%, 60%)。结论:女性宫颈阴道微生物群与人乳头瘤病毒(HPV)感染、宫颈上皮内瘤变和宫颈癌的发生发展密切相关,缺乏乳酸杆菌的CST是HPV感染和宫颈疾病、癌症发生的危险因素,而卷曲乳杆菌优势的CST可能促进高危HPV感染的清除并有利于宫颈上皮内瘤变的自然消退。
Abstract: Objective: To systematically evaluate the associations of cervical vaginal microbiota with human papillomavirus (HPV) infection, cervical intraepithelial neoplasias (CIN), and cervical cancer (CC). Methods: Studies on the associations of cervical vaginal microbiota of HPV infection, cervical intraepithelial neoplasias and cervical cancer since 2010 were searched in PUBMED, EMBASE, COCRANE LIBRARY and other databases by computer. After screening, systematic evaluation was conducted. Stata/MP 16.0 software was used for network meta-analysis of literatures. Results: After screening, 12 studies were included, involving a total of 1449 subjects. The most common vaginal community State types (CSTs) in the 12 studies were CST I: L. crispatus-dominant CST, CST III: L. iners-dominant CST, and CST IV: non-Lactobacillus-dominated CST. Meta analysis results confirmed that the women with non-Lactobacillus-dominant CST are more likely to HPV infection, high-risk HPV infection, cervical lesion and cervical cancer, including the consolidation odds ratio of HPV infection, OR = 1.78, 95%CI (1.29, 2.47), odds ratio of high risk HPV infection, OR = 1.36, 95%CI (0.97, 1.88), odds ratio of any cervical intraepithelial lesion or cancer, OR = 2.10, 95%CI (1.03, 4.27); for the elimination of high-risk HPV infection and regression of CIN2, the non-lactobacilli- dominant CST shows odds ratio with OR = 0.39, 95%CI (0.23, 0.66). The L. crispatus-dominant CST shows odds ratio with OR = 2.36, 95%CI (1.23, 4.52). The weighted pooled proportion of LOW lactobacillus CST in any HPV-positive group and high-risk HPV-positive group was the highest, with 52%, 95%CI (46%, 59%) and 49%, 95%CI (38%, 60%), respectively. Conclusion: Cervical vaginal microbiota and human papilloma virus (HPV) infection, cervical intraepithelial neoplasia is closely related to the occurrence of cervical cancer development, low number of lactobacilli CST is HPV infection and cervical disease, cancer risk factors, and lactobacillus crispatus can promote high-risk HPV infection of the advantages of the removal and help the natural regression of cervical intraepithelial neoplasia.
文章引用:秦丽, 朱莉, 王瑞雅, 任志帅, 郭玉琪. 宫颈阴道微生物群与HPV感染、宫颈上皮内瘤变及宫颈癌的关系:系统评价和网络荟萃分析[J]. 临床医学进展, 2021, 11(2): 698-713. https://doi.org/10.12677/ACM.2021.112101

参考文献

[1] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[2] Walboomers, J.M., Jacobs, M.V., Manos, M.M., Bosch, F.X., Kummer, J.A., Shah, K.V., et al. (1999) Human Papillomavirus Is a Necessary Cause of Invasive Cervical Cancer Worldwide. The Journal of Pathology, 189, 12-19. [Google Scholar] [CrossRef
[3] Ho, G.Y., Burk, R.D., Klein, S., Kadish, A.S., Chang, C.J., Palan, P., et al. (1995) Persistent Genital Human Papillomavirus Infection as a Risk Factor for Persistent Cervical Dysplasia. Journal of the National Cancer Institute, 87, 1365-1371. [Google Scholar] [CrossRef] [PubMed]
[4] Castle, P.E., Rodriguez, A.C., Burk, R.D., Herrero, R., Wacholder, S., Alfaro, M., et al. (2009) Short Term Persistence of Human Papillomavirus and Risk of Cervical Precancer and Cancer: Population Based Cohort Study. BMJ, 339, b2569. [Google Scholar] [CrossRef] [PubMed]
[5] Kjaer, S.K., Frederiksen, K., Munk, C. and Iftner T. (2010) Long-Term Absolute Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse Following Human Papillomavirus Infection: Role of Persistence. Journal of the National Cancer Institute, 102, 1478-1488. [Google Scholar] [CrossRef] [PubMed]
[6] Roura, E., Castellsague, X., Pawlita, M., Travier, N., Waterboer, T., Margall, N., et al. (2014) Smoking as a Major Risk Factor for Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort. International Journal of Cancer, 135, 453-466. [Google Scholar] [CrossRef] [PubMed]
[7] Eldridge, R.C., Pawlita, M., Wilson, L., Castle, P.E., Waterboer, T., Gravitt, P.E., et al. (2017) Smoking and Subsequent Human Papillomavirus Infection: A Mediation Analysis. Annals of Epidemiology, 27, 724-730.e1. [Google Scholar] [CrossRef] [PubMed]
[8] Moreno, V., Bosch, F.X., Munoz, N., Meijer, C.J., Shah, K.V., Walboomers, J.M., et al. (2002) Effect of Oral Contraceptives on Risk of Cervical Cancer in Women with Human Papillomavirus Infection: The IARC Multicentric Case-Control Study. Lancet, 359, 1085-1092. [Google Scholar] [CrossRef
[9] Munoz, N., Franceschi, S., Bosetti, C., Moreno, V., Herrero, R., Smith, J.S., et al. (2002) Role of Parity and Human Papillomavirus in Cervical Cancer: The IARC Multicentric Case-Control Study. Lancet, 359, 1093-1101. [Google Scholar] [CrossRef
[10] Castle, P.E. and Giuliano, A.R. (2003) Chapter 4: Genital Tract Infections, Cervical Inflammation, and Antioxidant Nutrients—Assessing Their Roles as Human Papillomavirus Cofactors. Journal of the National Cancer Institute Monographs, 31, 29-34. [Google Scholar] [CrossRef] [PubMed]
[11] Curty, G., de Carvalho, P.S. and Soares, M.A. (2019) The Role of the Cervicovaginal Microbiome on the Genesis and as a Biomarker of Premalignant Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer. International journal of molecular sciences, 21, 222. [Google Scholar] [CrossRef] [PubMed]
[12] Witkin, S.S. and Linhares, I.M. (2017) Why Do Lactobacilli Dominate the Human Vaginal Microbiota? BJOG, 124, 606-611. [Google Scholar] [CrossRef] [PubMed]
[13] Mitra, A., Macintyre, D.A., Marchesi, J.R., Lee, Y.S., Bennett, P.R. and Kyrgiou M. (2016) The Vaginal Microbiota, Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia: What Do We Know and Where Are We Going Next? Microbiome, 4, Article No. 58. [Google Scholar] [CrossRef] [PubMed]
[14] Ravel, J., Gajer, P., Abdo, Z., Maria Schneider, G., Koenig, S.S.K., McCulle, S.L., et al. (2011) Vaginal Microbiome of Reproductive-Age Women. Proceedings of the National Academy of Sciences of the United States of America, 108, 4680-4687. [Google Scholar] [CrossRef] [PubMed]
[15] Agency for Healthcare Research and Quality (US) (2020) Cross-Sectional/Prevalence Study Quality. http://www.ncbi.nlm.nih.gov/books/NBK35156/.
[16] Lewis, J.R. and Sauro, J. (2006) When 100% Really Isn’t 100%: Improving the Accuracy of Small-Sample Estimates of Completion Rates. Journal of Usability Studies, 1, 136-150.
[17] Gao, W., Weng, J., Gao, Y. and Chen, X. (2013) Comparison of the Vaginal Microbiota Diversity of Women with and without Human Papillomavirus Infection: A Cross-Sectional Study. BMC Infectious Diseases, 13, Article No. 271.
[18] Shannon, B., Yi, T.J., Perusini, S., Gajer, P., Ma, B, Humphrys, M.S., et al. (2017) Association of HPV Infection and Clearance with Cervicovaginal Immunology and the Vaginal Microbiota. Mucosal Immunology, 10, 1310-1319.
[19] Chen, Y., Qiu, X., Wang, W., Li, D., Wu, A., Hong, Z., et al. (2020) Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia Progression are Associated with Increased Vaginal Microbiome Diversity in a Chinese Cohort. BMC Infectious Diseases, 20, 629. [Google Scholar] [CrossRef] [PubMed]
[20] Brotman, R.M., Shardell, M.D., Gajer P., Gajer, P., Kathleen Tracy, J., Zenilman, J.M., et al. (2014) Interplay between the Temporal Dynamics of the Vaginal Microbiota and Human Papillomavirus Detection. The Journal of Infectious Diseases, 210, 1723-1733. [Google Scholar] [CrossRef] [PubMed]
[21] Borgdorff, H., Tsivtsivadze, E., Verhelst, R., Marzorati, M., Jurriaans, S., Ndayisaba, G.F., et al. (2014) Lactobacillus-Dominated Cervicovaginal Microbiota Associated with Reduced HIV/STI Prevalence and Genital HIV Viral Load in African Women. The ISME Journal, 8, 1781-1793.
[22] Dareng, E.O., Ma, B., Famooto, A.O., Akarolo-Anthony, S.N., Offiong, R.A., Olaniyan, O., et al. (2016) Prevalent High-Risk HPV Infection and Vaginal Microbiota in Nigerian Women. Epidemiology & Infection, 144, 123-137. [Google Scholar] [CrossRef
[23] Di Paola, M., Sani, C., Clemente, A.M., Iossa, A., Perissi, E., Castronovo, G., et al. (2017) Characterization of Cervico-Vaginal Microbiota in Women Developing Persistent High-Risk Human Papillomavirus Infection. Scientific Reports, 7, Article No. 10200. [Google Scholar] [CrossRef] [PubMed]
[24] Mitra, A., MacIntyre, D.A., Lee, Y.S., Smith, A., Marchesi, J.R., Lehne, B., et al. (2015) Cervical Intraepithelial Neoplasia Disease Progression is Associated with Increased Vaginal Microbiome Diversity. Scientific Reports, 5, Article ID: 16865. [Google Scholar] [CrossRef] [PubMed]
[25] Zhang, C., Liu, Y., Gao, W., Pan, Y., Gao, Y., Shen, J., et al. (2018) The Direct and Indirect Association of Cervical Microbiota with the Risk of Cervical Intraepithelial Neoplasia. Cancer Medicine, 7, 2172-2179. [Google Scholar] [CrossRef] [PubMed]
[26] Audirac-Chalifour, A., Torres-Poveda, K., Bahena-Román, M., Téllez-Sosa, J., Martínez-Barnetche, J., Cortina-Ceballos, B., et al. (2016) Cervical Microbiome and Cytokine Profile at Various Stages of Cervical Cancer: A Pilot Study. PLoS ONE, 11, e0153274. [Google Scholar] [CrossRef] [PubMed]
[27] Seo, S.S., Oh, H.Y., Lee, J.K., Kong, J.S., Lee, D.O. and Kim, M.K. (2016) Combined Effect of Diet and Cervical Microbiome on the Risk of Cervical Intraepithelial Neoplasia. Clinical Nutrition, 35, 1434-1441. [Google Scholar] [CrossRef] [PubMed]
[28] Mitra, A., MacIntyre, D. A., Ntritsos, G., Smith, A., Tsilidis, K.K., Marchesi, J.R., Bennett, P.R., Moscicki, A.B. and Kyrgiou, M. (2020) The Vaginal Microbiota Associates with the Regression of Untreated Cervical Intraepithelial Neoplasia 2 Lesions. Nature Communications, 11, Article No. 1999. [Google Scholar] [CrossRef] [PubMed]
[29] Tu, Y.-K. (2016) Node-Splitting Generalized Linear Mixed Models for Evaluation of Inconsistency in Network Meta-Analysis. Value in Health the Journal of the International Society for Pharmacoeconomics & Outcomes Research, 19, 957-963. [Google Scholar] [CrossRef] [PubMed]
[30] 张天嵩, 董圣杰, 周支瑞. 高级meta分析方法: 基于stata实现[M]. 上海: 复旦大学出版, 2015.
[31] Laniewski, P., Cui, H., Roe, D.J., Barnes, D., Goulder, A., Monk, B.J., et al. (2019) Features of the Cervicovaginal Microenvironment Drive Cancer Biomarker Signatures in Patients Across Cervical Carcinogenesis. Scientific Reports, 9, Article No. 7333. [Google Scholar] [CrossRef] [PubMed]
[32] Ilhan, Z.E., Laniewski, P., Thomas, N., Roe, D.J., Chase, D.M. and Herbst-Kralovetz, M.M. (2019) Deciphering the Complex Interplay between Microbiota, HPV, Inflammation and Cancer through Cervicovaginal Metabolic Profiling. EBioMedicine, 44, 675-690. [Google Scholar] [CrossRef] [PubMed]